Synthesis and antibacterial activity of N4-mono alkyl derivatives of novel glycopeptide LYV07ww01

Shao, Chang Lun; Zhou, Weicheng; Zhang, Shunli; Wei, Wei; Ruan, Lingao; Jin, Yiping; Sun, Xuewen; Huang, Yanqin

doi:10.1016/j.bmcl.2011.09.045

Cited by 3 publications

(1 citation statement)

References 14 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The inhibitory activity of glycopeptide antibiotic SKF 104662 was generally equivalent to the activities of vancomycin, teicoplanin and daptomycin against selected gram positive bacteria such as S. epidermidis and S. haemolyticus [ 8 ] . 31 N(4)-mono alkyl derivatives of novel glycopeptide LYV07WW01 were synthesized by reductive alkylation and their benzyl derivatives showed potent antibacterial activity, especially against vancomycin-resistant enterococci and penicillin-resistant Streptococcus pneumoniae [ 9 ] . A multivalent polymer of vancomycin, synthesized via ring opening metathesis polymerization (ROMP) exhibited signifi cant enhancement of antibacterial activity against vancomycin-resistant enterococi (VRE) [ 10 ] .…”

mentioning

confidence: 99%

Antimicrobial Glycopeptides: Synthesis and Antibacterial Activity of N-linked and O-linked Smaller Chain Glycopeptides

Nagarajan¹,

Taleuzzamman

Kumar³

et al. 2013

Drug Res (Stuttg)

View full text Add to dashboard Cite

Our objective is to synthesize the smaller chain N-linked and O-linked glycopeptides using sugars belong to mono, di and polysaccharides, with the efforts mainly directed towards the identification of antibacterial compounds. 7 glycopeptides, viz., Arg-Asn-Mannose, Arg-Asn-Lactose, His-Asn-Mannose, His-Asn-Lactose (N-glycopeptides), Arg-Ser-Lactose, Arg-Thr-Lactose, Arg-Thr-Starch (O-glycopeptides) were prepared by dicyclohexyl carbodimide (DCC) coupling for amino acids using microwave oven (50W power; 15 min) and activated and coupled with respective sugar moieties using microwave oven at 120 W for 20-25 min. The column eluted compounds were tested for disc diffusion assay using 3 gram positive S. aureus, B. subtilis, S. caprae and 3 gram negative E. coli, P. aeruginosa and S. sonnei strains at different concentrations predicted by pH and inhibitory concentrations. One of the test glycopeptide, His-Asn-Lactose was found to be very effective against all the microbial strains tested and 3 other Test Compounds, viz., His-Asn-Mannose, Arg-Thr-Lactose and Arg-Thr-Starch are also proved to be effective against 2 gram positive and 2 gram negative strains tested. Maximum activity was observed at a concentration of 450 μg/ml (747.51 µM) for the N-glycopeptide His-Asn-Lactose with the corresponding zonal inhibition diameters (15 mm; 19 mm; 14 mm; 18 mm; 16 mm; 17 mm) against S. aureus, B. subtilis, S. caprae, E. coli, P. aeruginosa, S. sonnei. This is the first evidence based report that our N-glycopeptide, His-Asn-Lactose tested, has shown antibacterial action against both gram positive and gram negative strains. Further in vivo testing and clinical studies will make sure to position our potent small chain N-glycopeptide in the arsenal of new broad spectrum anti-gram positive and negative agent.

show abstract

mentioning

confidence: 99%

Antimicrobial Glycopeptides: Synthesis and Antibacterial Activity of N-linked and O-linked Smaller Chain Glycopeptides

Nagarajan¹,

Taleuzzamman

Kumar³

et al. 2013

Drug Res (Stuttg)

View full text Add to dashboard Cite

show abstract

Peptidomimetics in Medicinal Chemistry: The Art of Transforming Peptides to Drugs

Nagarajan,

Kapoor

2023

Recent Advances in Pharmaceutical Innovation and Research

View full text Add to dashboard Cite

The search for novel treatment strategies forStreptococcus pneumoniaeinfections

Cools

Delputte

Cos

2021

FEMS Microbiology Reviews

View full text Add to dashboard Cite

This review provides an overview of the most important novel treatment strategies against Streptococcus pneumoniae infections published over the past 10 years. The pneumococcus causes the majority of community-acquired bacterial pneumonia cases, and it is one of the prime pathogens in bacterial meningitis. Over the last 10 years, extensive research has been conducted to prevent severe pneumococcal infections, with a major focus on (i) boosting the host immune system and (ii) discovering novel antibacterials. Boosting the immune system can be done in two ways, either by actively modulating host immunity, mostly through administration of selective antibodies, or by interfering with pneumococcal virulence factors, thereby supporting the host immune system to effectively overcome an infection. While several of such experimental therapies are promising, few have evolved to clinical trials. The discovery of novel antibacterials is hampered by the high research and development costs versus the relatively low revenues for the pharmaceutical industry. Nevertheless, novel enzymatic assays and target-based drug design, allow the identification of targets and the development of novel molecules to effectively treat this life-threatening pathogen.

show abstract

Synthesis and antibacterial activity of N4-mono alkyl derivatives of novel glycopeptide LYV07ww01

Cited by 3 publications

References 14 publications

Antimicrobial Glycopeptides: Synthesis and Antibacterial Activity of N-linked and O-linked Smaller Chain Glycopeptides

Antimicrobial Glycopeptides: Synthesis and Antibacterial Activity of N-linked and O-linked Smaller Chain Glycopeptides

Peptidomimetics in Medicinal Chemistry: The Art of Transforming Peptides to Drugs

The search for novel treatment strategies forStreptococcus pneumoniaeinfections

Contact Info

Product

Resources

About